Optum guides providers through important upcoming formulary updates
Close
Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
September 13, 2018 - The FDA announced the discontinuation of Bristol Myers Squibb’s Daklinza (daclatasvir) 90mg tablets.
Download PDF
Return to publications
